Vanguard Global Advisers’s Definium Therapeutics DFTX Stock Holding History
Bought
Maintained
Sold
Other funds holding DFTX
Vanguard Global Advisers's DFTX Position: Q3 2026 in Review
Vanguard Global Advisers increased its Definium Therapeutics (DFTX) stake by 5.7% in Q3 2026, buying an estimated $138K and bringing the position to 60,216 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1161.
Vanguard Global Advisers first reported a position in DFTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.68M in Q2 2026. 353 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.
- Vanguard Global Advisers held 60,216 shares of Definium Therapeutics worth $2.29M as of Q3 2026.
- Vanguard Global Advisers bought 3,274 Definium Therapeutics shares in Q3 2026, an estimated $138K.
- Definium Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1161 holding.
- Vanguard Global Advisers first reported a position in Definium Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Definium Therapeutics position peaked at $2.68M in Q2 2026.
- 353 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.